File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Managing cardiovascular risk of macrolides: systematic review and meta-analysis

TitleManaging cardiovascular risk of macrolides: systematic review and meta-analysis
Authors
Issue Date2017
PublisherAdis International Ltd. The Journal's web site is located at http://www.springer.com/adis/journal/40264
Citation
Drug Safety, 2017, v. 40 n. 8, p. 663-677 How to Cite?
AbstractIntroduction It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use. Methods Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ae18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration's tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines. Results Observational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. Limitations The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity. Conclusions More studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.
Persistent Identifierhttp://hdl.handle.net/10722/241624
ISSN
2019 Impact Factor: 3.442
2015 SCImago Journal Rankings: 1.359
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, YS-
dc.contributor.authorChan, EW-
dc.contributor.authorAnand, S-
dc.contributor.authorWorsley, AJ-
dc.contributor.authorWong, ICK-
dc.date.accessioned2017-06-20T01:46:15Z-
dc.date.available2017-06-20T01:46:15Z-
dc.date.issued2017-
dc.identifier.citationDrug Safety, 2017, v. 40 n. 8, p. 663-677-
dc.identifier.issn0114-5916-
dc.identifier.urihttp://hdl.handle.net/10722/241624-
dc.description.abstractIntroduction It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use. Methods Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ae<yen>18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration's tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines. Results Observational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. Limitations The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity. Conclusions More studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.-
dc.languageeng-
dc.publisherAdis International Ltd. The Journal's web site is located at http://www.springer.com/adis/journal/40264-
dc.relation.ispartofDrug Safety-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.titleManaging cardiovascular risk of macrolides: systematic review and meta-analysis-
dc.typeArticle-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailAnand, S: shweta@hku.hk-
dc.identifier.emailWorsley, AJ: alanwor@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityWorsley, AJ=rp01395-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s40264-017-0533-2-
dc.identifier.pmid28397186-
dc.identifier.scopuseid_2-s2.0-85017198820-
dc.identifier.hkuros272549-
dc.identifier.volume40-
dc.identifier.issue8-
dc.identifier.spage663-
dc.identifier.epage677-
dc.identifier.isiWOS:000406239200003-
dc.publisher.placeNew Zealand-
dc.identifier.issnl0114-5916-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats